IBI3001
As of the edition of 20 October 2026, IBI3001 is a drug known only by a code name: in active development; acts on CD276 and EGFR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Code name only
- Registered trials
- 1, 0 stopped early
- Disease areas
- Cancer; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innovent Biologics | Lead sponsor of trials | 2025 to now |